Literature DB >> 7686363

Structure-activity analysis of synthetic alpha-thrombin-receptor-activating peptides.

E Van Obberghen-Schilling1, U B Rasmussen, V Vouret-Craviari, K U Lentes, A Pavirani, J Pouysségur.   

Abstract

alpha-Thrombin stimulates G-protein-coupled effectors leading to secretion and aggregation in human platelets, and to a mitogenic response in CCL39 hamster fibroblasts. alpha-Thrombin receptors can be activated by synthetic peptides corresponding to the receptor sequence starting with serine-42, at the proposed cleavage site. We have previously determined that the agonist domain of receptor-activating peptides resides within the five N-terminal residues [Vouret-Craviari, Van Obberghen-Schilling, Rasmussen, Pavirani, Lecocq and Pouysségur (1992) Mol. Biol. Cell. 3, 95-102], although the 7-residue peptide (SFFLRNP) corresponding to the hamster alpha-thrombin receptor was 10 times more potent than the 5-residue peptide for activation of human platelets. In the present study we have analysed the role of individual amino acids in receptor activation by using a series of modified hexa- or hepta-peptides derived from the human alpha-thrombin-receptor sequence. Cellular events examined here include phospholipase C activation, adenylyl cyclase inhibition and DNA synthesis stimulation in non-transformed CCL39 fibroblasts and a tumorigenic variant of that line (A71 cells). Modification of the peptide sequence had similar functional consequence for each of the assays described, indicating that either a unique receptor or pharmacologically indistinguishable receptor subtypes activate distinct G-protein signalling pathways. Furthermore, we found that: (1) the N-terminal serine can be replaced by small or intermediately sized amino acids (+/- hydroxyl groups) without loss of activity. However, its replacement by an aromatic side-chain or omission of the N-terminal amino group severely reduces activity. (2) An aromatic side-chain on the penultimate N-terminal residue appears to play a critical role since phenylalanine in this position can be substituted by tyrosine without complete loss of activity whereas an alanine in its place is not tolerated. (3) Deletion of the first, second or third N-terminal residue leads to a loss of activity, suggesting that a defined spacing of more than one structural component may be important for ligand-receptor interaction. Finally, we did not observe an antagonistic effect of the inactive peptides on phospholipase C activation or DNA synthesis induced by alpha-thrombin (1 nM) or SFLLRNP (3 microM).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7686363      PMCID: PMC1134165          DOI: 10.1042/bj2920667

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  27 in total

1.  Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation.

Authors:  T K Vu; D T Hung; V I Wheaton; S R Coughlin
Journal:  Cell       Date:  1991-03-22       Impact factor: 41.582

2.  Three-dimensional models of neurotransmitter G-binding protein-coupled receptors.

Authors:  M F Hibert; S Trumpp-Kallmeyer; A Bruinvels; J Hoflack
Journal:  Mol Pharmacol       Date:  1991-07       Impact factor: 4.436

3.  The structural elements of hirudin which bind to the fibrinogen recognition site of thrombin are exclusively located within its acidic C-terminal tail.

Authors:  J Y Chang; P K Ngai; H Rink; S Dennis; J M Schlaeppi
Journal:  FEBS Lett       Date:  1990-02-26       Impact factor: 4.124

4.  Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis.

Authors:  M Heras; J H Chesebro; M W Webster; J S Mruk; D E Grill; W J Penny; E J Bowie; L Badimon; V Fuster
Journal:  Circulation       Date:  1990-10       Impact factor: 29.690

5.  Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy.

Authors:  R Henderson; J M Baldwin; T A Ceska; F Zemlin; E Beckmann; K H Downing
Journal:  J Mol Biol       Date:  1990-06-20       Impact factor: 5.469

6.  Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition.

Authors:  I K Jang; H K Gold; A A Ziskind; R C Leinbach; J T Fallon; D Collen
Journal:  Circulation       Date:  1990-01       Impact factor: 29.690

7.  Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits.

Authors:  I J Sarembock; S D Gertz; L W Gimple; R M Owen; E R Powers; W C Roberts
Journal:  Circulation       Date:  1991-07       Impact factor: 29.690

8.  Minimal sequence requirement of thrombin receptor agonist peptide.

Authors:  K Y Hui; J A Jakubowski; V L Wyss; E L Angleton
Journal:  Biochem Biophys Res Commun       Date:  1992-04-30       Impact factor: 3.575

9.  Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor.

Authors:  M Heras; J H Chesebro; W J Penny; K R Bailey; L Badimon; V Fuster
Journal:  Circulation       Date:  1989-03       Impact factor: 29.690

10.  Deregulation of hamster fibroblast proliferation by mutated ras oncogenes is not mediated by constitutive activation of phosphoinositide-specific phospholipase C.

Authors:  K Seuwen; A Lagarde; J Pouysségur
Journal:  EMBO J       Date:  1988-01       Impact factor: 11.598

View more
  3 in total

Review 1.  Cellular consequences of thrombin-receptor activation.

Authors:  R J Grand; A S Turnell; P W Grabham
Journal:  Biochem J       Date:  1996-01-15       Impact factor: 3.857

2.  Regulation of neurite outgrowth from differentiated human neuroepithelial cells: a comparison of the activities of prothrombin and thrombin.

Authors:  A S Turnell; D P Brant; G R Brown; M Finney; P H Gallimore; C J Kirk; T R Pagliuca; C J Campbell; R H Michell; R J Grand
Journal:  Biochem J       Date:  1995-06-15       Impact factor: 3.857

3.  Thrombin stimulates fibroblast procollagen production via proteolytic activation of protease-activated receptor 1.

Authors:  R C Chambers; K Dabbagh; R J McAnulty; A J Gray; O P Blanc-Brude; G J Laurent
Journal:  Biochem J       Date:  1998-07-01       Impact factor: 3.857

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.